Cargando…

Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy

INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Steenwijk, Martijn D., Amiri, Houshang, Schoonheim, Menno M., de Sitter, Alexandra, Barkhof, Frederik, Pouwels, Petra J.W., Vrenken, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540882/
https://www.ncbi.nlm.nih.gov/pubmed/28794970
http://dx.doi.org/10.1016/j.nicl.2017.06.034
_version_ 1783254698715774976
author Steenwijk, Martijn D.
Amiri, Houshang
Schoonheim, Menno M.
de Sitter, Alexandra
Barkhof, Frederik
Pouwels, Petra J.W.
Vrenken, Hugo
author_facet Steenwijk, Martijn D.
Amiri, Houshang
Schoonheim, Menno M.
de Sitter, Alexandra
Barkhof, Frederik
Pouwels, Petra J.W.
Vrenken, Hugo
author_sort Steenwijk, Martijn D.
collection PubMed
description INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. Here we perform a validation of MSmetrix against established methods in simulated and in vivo MRI data. METHODS: Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20 matched healthy controls. In fifty of the MS patients a second time point was available. In this subgroup, we additionally analyzed the whole-brain and GM volume change using the longitudinal pipeline of MSmetrix and compared the results with those of FreeSurfer (longitudinal pipeline) and SIENA. RESULTS: In the simulated data, SIENAX displayed the smallest average deviation compared with the reference whole-brain volume (+ 19.56 ± 10.34 mL), followed by MSmetrix (− 38.15 ± 17.77 mL), SPM (− 42.99 ± 17.12 mL) and FreeSurfer (− 78.51 ± 12.68 mL). A similar pattern was seen in vivo. Among the cross-sectional methods, Deming regression analyses revealed proportional errors particularly in MSmetrix and SPM. The mean difference percentage brain volume change (PBVC) was lowest between longitudinal MSmetrix and SIENA (+ 0.16 ± 0.91%). A strong proportional error was present between longitudinal percentage gray matter volume change (PGVC) measures of MSmetrix and FreeSurfer (slope = 2.48). All longitudinal methods were sensitive to the MRI hardware upgrade that occurred during the time of the study. CONCLUSION: MSmetrix, FreeSurfer, FSL and SPM show differences in atrophy measurements, even at the whole-brain level, that are large compared to typical atrophy rates observed in MS. Especially striking are the proportional errors between methods. Cross-sectional MSmetrix behaved similarly to SPM, both in terms of mean volume difference as well as proportional error. Longitudinal MSmetrix behaved most similar to SIENA. Our results indicate that brain volume measurement and normalization from T1-weighted images remains an unsolved problem that requires much more attention.
format Online
Article
Text
id pubmed-5540882
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55408822017-08-09 Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy Steenwijk, Martijn D. Amiri, Houshang Schoonheim, Menno M. de Sitter, Alexandra Barkhof, Frederik Pouwels, Petra J.W. Vrenken, Hugo Neuroimage Clin Regular Article INTRODUCTION: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. Here we perform a validation of MSmetrix against established methods in simulated and in vivo MRI data. METHODS: Whole-brain and gray matter (GM) volume were measured with the cross-sectional pipeline of MSmetrix and compared to the outcomes of FreeSurfer (cross-sectional pipeline), SIENAX and SPM. For this comparison we investigated 20 simulated brain images, as well as in vivo data from 100 MS patients and 20 matched healthy controls. In fifty of the MS patients a second time point was available. In this subgroup, we additionally analyzed the whole-brain and GM volume change using the longitudinal pipeline of MSmetrix and compared the results with those of FreeSurfer (longitudinal pipeline) and SIENA. RESULTS: In the simulated data, SIENAX displayed the smallest average deviation compared with the reference whole-brain volume (+ 19.56 ± 10.34 mL), followed by MSmetrix (− 38.15 ± 17.77 mL), SPM (− 42.99 ± 17.12 mL) and FreeSurfer (− 78.51 ± 12.68 mL). A similar pattern was seen in vivo. Among the cross-sectional methods, Deming regression analyses revealed proportional errors particularly in MSmetrix and SPM. The mean difference percentage brain volume change (PBVC) was lowest between longitudinal MSmetrix and SIENA (+ 0.16 ± 0.91%). A strong proportional error was present between longitudinal percentage gray matter volume change (PGVC) measures of MSmetrix and FreeSurfer (slope = 2.48). All longitudinal methods were sensitive to the MRI hardware upgrade that occurred during the time of the study. CONCLUSION: MSmetrix, FreeSurfer, FSL and SPM show differences in atrophy measurements, even at the whole-brain level, that are large compared to typical atrophy rates observed in MS. Especially striking are the proportional errors between methods. Cross-sectional MSmetrix behaved similarly to SPM, both in terms of mean volume difference as well as proportional error. Longitudinal MSmetrix behaved most similar to SIENA. Our results indicate that brain volume measurement and normalization from T1-weighted images remains an unsolved problem that requires much more attention. Elsevier 2017-06-30 /pmc/articles/PMC5540882/ /pubmed/28794970 http://dx.doi.org/10.1016/j.nicl.2017.06.034 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regular Article
Steenwijk, Martijn D.
Amiri, Houshang
Schoonheim, Menno M.
de Sitter, Alexandra
Barkhof, Frederik
Pouwels, Petra J.W.
Vrenken, Hugo
Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title_full Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title_fullStr Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title_full_unstemmed Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title_short Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
title_sort agreement of msmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540882/
https://www.ncbi.nlm.nih.gov/pubmed/28794970
http://dx.doi.org/10.1016/j.nicl.2017.06.034
work_keys_str_mv AT steenwijkmartijnd agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT amirihoushang agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT schoonheimmennom agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT desitteralexandra agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT barkhoffrederik agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT pouwelspetrajw agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy
AT vrenkenhugo agreementofmsmetrixwithestablishedmethodsformeasuringcrosssectionalandlongitudinalbrainatrophy